THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Friday reported a loss of $12.7 million in its fourth quarter.
The Thousand Oaks, California-based company said it had a loss of $1.19 per share.
The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $3.82 per share.
The drug developer posted revenue of $32.8 million in the period.
For the year, the company reported that its loss narrowed to $85.4 million, or $11.41 per share. Revenue was reported as $128.9 million.
Atara Biotherapeutics shares have dropped 48% since the beginning of the year. In the final minutes of trading on Friday, shares hit $6.88, a drop of 60% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ATRA at https://www.zacks.com/ap/ATRA
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.